Chosa Oncology (CHOSA) investor relations material

Presentation of new clinical data and highlights

• Platin-DRP® scores correlated with significant improvements in overall and progression-free survival in advanced NSCLC patients treated with platinum-based chemotherapy, with a hazard ratio of 0.602 for overall survival and 0.697 for progression-free survival.

• Median overall survival was 16.9 months for high Platin-DRP® score patients versus 5.5 months for low-score patients, indicating a clinically meaningful benefit.

• No significant interaction was found between chemotherapy regimen (cisplatin vs. carboplatin) and DRP score, supporting the biomarker's applicability across both agents.

• No validated predictive biomarker exists for cisplatin or carboplatin; DRP may guide both clinical trials and practice.

• Ongoing validation studies are evaluating the predictive role of Platin-DRP® in platinum plus immunotherapy settings.

Commercialization and market strategy

• Main users are oncologists for treatment planning and pharma companies for drug development.

• Revenue strategies include out-licensing to diagnostic companies and pharma, with royalties or case-by-case deals.

• Patent protection on the 205-gene algorithm runs until 2038.

• Geographic focus is balanced between US, Europe, and China, with commercial upside strongest in the US.

• Partnerships could include trade sales, licensing, or providing the algorithm to companies with established logistics.

Operational and financial outlook

• Annual burn rate is around SEK 7 million, with potential to increase as activities scale.

• Liquidity is managed carefully, and visibility efforts include webinars and investor roadshows.

• Results will be shared with potential partners to drive business development.

• Open to grants and financing opportunities, though listed status may limit some options.